Advancements in the Management of R/R AML: ASH 2024 - Episode 8

Integrating Revumenib Into Current R/R AML Treatment Paradigms

January 29, 2025

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO , James Blachly, MD, Aaron Goldberg, MD, PhD Memorial Sloan Kettering Cancer Center, Rami Komrokji, MD, Gabe Mannis, MD , Michael J. Thirman, MD

Panelists discuss key findings from the phase I/II study of the all-oral SAVE combination with revumenib in relapsed/refractory acute monocytic leukemia (R/R AML), the impact of the regimen's success in achieving high response and MRD negativity rates on integrating all-oral therapies into the treatment paradigm for R/R AML, particularly in patients with prior venetoclax or transplant exposure, and the potential role of revumenib in current treatment paradigms for R/R AML.

EP. 1: Treatment Strategies for Relapsed/Refractory AML Patients

EP. 2: Treatment Goals and Unmet Needs in R/R AML

EP. 3: Navigating Challenges in Second- and Third-Line AML Therapy

EP. 4: Revumenib’s FDA Approval and Clinical Implications

EP. 5: Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

EP. 6: Adverse Event Management and Patient Safety With Revumenib

EP. 7: MRD Testing and the Role of Revumenib in Treatment Response

Now Viewing

EP. 8: Integrating Revumenib Into Current R/R AML Treatment Paradigms

Video content above is prompted by the following:

Dr. LeBlanc to ask Dr. Goldberg: Briefly comment on the key findings presented from the Pphase I/II study of the all-oral “SAVE” combination with revumenib in R/R AML.(Issa, GC, et al. ASH 2024. Oral Abstract 216, Session: 616 or pg. 13)
Dr. LeBlanc to ask Dr. Blachly: How does the success of the SAVE regimen in achieving high response and MRD negativity rates influence the integration of all-oral therapies into the treatment paradigm for R/R AML, particularly in patient populations with prior venetoclax or transplant exposure?
Dr. LeBlanc to ask GROUP: Where do you see revumenib fitting in your current treatment paradigms for R/R AML?